Ayala Pharmaceuticals, Inc. (ADXS) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Monmouth Junction, NJ, 美国. 现任CEO为 Kenneth A. Berlin.
ADXS 拥有 IPO日期为 2020-05-08, 20 名全职员工, 在 Other OTC, 市值为 $25.71M.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
